CTOs on the Move

Whitman-Walker Health

www.whitman-walker.org

 
Social Media Commenting Policy Welcome! Whitman-Walker maintains social media channels as a service to our supporters who wish to keep updated on news from WWH and possibly share information with one another. We are glad to have you join us! We ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Scott Tambert
Director of Technology Solutions and Information Security Officer Profile

Similar Companies

AAA Pharmaceutical

AAA Pharmaceutical is a Lumberton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nivagen Pharmaceuticals, Inc.

Nivagen is engaged in the development, acquisition and sales of generic prescription drugs and over the counter products for the North American market. Our vision is to deliver high quality products at affordable prices by leveraging global partnerships with the best FDA approved manufacturing facilities across the world.

CSI TESTING

CSI TESTING Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cylene Pharmaceuticals

Cylene Pharmaceuticals is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immunic

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.